Akamis Bio develops systemically administered tumor-specific immuno-gene therapies for solid tumors, initially targeting locally advanced rectal cancer.
Akamis Bio is a clinical-stage oncology company developing oncolytic immunotherapies that treat solid tumors, with an initial focus on mismatch repair-proficient locally advanced rectal cancer. Its T-SIGn platform engineers viral vectors that attack tumor tissue while delivering immune-modulating payloads, such as a CD40 agonist antibody, directly to the tumor microenvironment.
The pipeline centers on NG-350A, an intravenously delivered oncolytic immunotherapy studied with chemoradiotherapy in the Phase 1b FORTRESS trial as an organ-preserving alternative to surgery for rectal cancer patients. T-SIGn therapeutics differ by turning tumor cells themselves into local factories for immunotherapeutic proteins, delivering their payloads directly inside the tumor microenvironment.
